New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc. (HIND) vs Lexaria Bioscience Corp. (LEXX)

Vyome Holdings, Inc. and Lexaria Bioscience Corp. are both Biotechnology companies. Vyome Holdings, Inc. and Lexaria Bioscience Corp. are of similar size ($10.2M and $9.5M). Lexaria Bioscience Corp. grew revenue faster over the last twelve months: 52.0% against −55.6%. Lexaria Bioscience Corp. has the higher net margin (−1,686.1% vs −2,453.9%) and the lower return on invested capital (−662.6% vs 0.00%). Across the 18 metrics below, Lexaria Bioscience Corp. leads on 11 and Vyome Holdings, Inc. on 7.

Valuation

Metric HIND LEXX Biotechnology median
P/E n/m n/m 8.49
P/S 55.90 12.30 8.56
P/B 1.31 1.53 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 12.73 5.63 8.00
Earnings yield (48.42%) (129.52%) (35.81%)
Free cash flow yield (52.40%) (112.89%) (25.41%)

Profitability

Metric HIND LEXX Biotechnology median
Gross margin 50.39% 99.62% 70.18%
Operating margin (2,851.63%) (1,683.06%) 0.00%
Net margin (2,453.92%) (1,686.05%) 0.00%
Free cash flow margin (2,928.92%) (1,494.56%) 0.00%
Return on equity (71.85%) (162.60%) (51.58%)
Return on assets (48.02%) (134.20%) (45.91%)
Return on invested capital 0.00% (662.56%) 0.00%

Growth

Metric HIND LEXX Biotechnology median
Revenue growth (TTM) (55.55%) 52.04% 7.20%
EPS growth (last fiscal year) 99.92% (40.43%) 29.04%
Revenue growth, 5-year CAGR (50.98%) 17.53% 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric HIND LEXX Biotechnology median
Debt to equity 0.05 0.00 0.00
Current ratio 3.68 10.60 4.79
Net debt to EBITDA 0.48 0.17 1.01

Dividend

Metric HIND LEXX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric HIND LEXX Biotechnology median
Market cap 10.18m 9.46m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack